(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-0.15%) $77.99
(0.37%) $2.15
(0.06%) $2 310.10
(0.36%) $26.79
(0.09%) $966.20
(-0.38%) $0.929
(-1.10%) $10.87
(-0.13%) $0.797
(0.52%) $91.61
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States...
Stats | |
---|---|
今日成交量 | 308 100 |
平均成交量 | 251 405 |
市值 | 259.75B |
EPS | ¥0 ( 2024-02-13 ) |
下一个收益日期 | ( ¥59.41 ) 2024-05-08 |
Last Dividend | ¥65.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 19.69 |
ATR14 | ¥4.42 (0.07%) |
音量 相关性
Sawai Group Holdings Co., 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Sawai Group Holdings Co., 相关性 - 货币/商品
Sawai Group Holdings Co., 财务报表
Annual | 2022 |
营收: | ¥200.34B |
毛利润: | ¥62.63B (31.26 %) |
EPS: | ¥289.26 |
FY | 2022 |
营收: | ¥200.34B |
毛利润: | ¥62.63B (31.26 %) |
EPS: | ¥289.26 |
FY | 2022 |
营收: | ¥193.82B |
毛利润: | ¥66.65B (34.39 %) |
EPS: | ¥-957.37 |
Financial Reports:
No articles found.
Sawai Group Holdings Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥65.00 (N/A) |
¥0 (N/A) |
¥65.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥65.00 | 2021-09-29 |
Last Dividend | ¥65.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | ¥260.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.11 | -- |
Div. Sustainability Score | 9.15 | |
Div.Growth Potential Score | 4.60 | |
Div. Directional Score | 6.88 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8369.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7762.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6937.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
6294.T | Ex Dividend Knight | 2024-03-28 | Annually | 0 | 0.00% | |
5018.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
4220.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3434.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2540.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
9468.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8097.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0749 | 1.500 | 8.50 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0392 | 1.200 | 8.69 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0735 | 1.500 | -0.294 | -0.441 | [0.1 - 1] |
payoutRatioTTM | 0.372 | -1.000 | 6.28 | -6.28 | [0 - 1] |
currentRatioTTM | 2.18 | 0.800 | 4.09 | 3.27 | [1 - 3] |
quickRatioTTM | 0.782 | 0.800 | -0.108 | -0.0867 | [0.8 - 2.5] |
cashRatioTTM | 0.254 | 1.500 | 9.70 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.229 | -1.500 | 6.19 | -9.28 | [0 - 0.6] |
interestCoverageTTM | 40.11 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 544.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -35.66 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.425 | -1.500 | 8.30 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.305 | 1.000 | 8.25 | 8.25 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0968 | 1.000 | -0.0640 | -0.0640 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.267 | 1.000 | 9.63 | 9.63 | [0.2 - 2] |
assetTurnoverTTM | 0.524 | 0.800 | 9.84 | 7.87 | [0.5 - 2] |
Total Score | 9.15 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 16.95 | 1.000 | 8.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0735 | 2.50 | -0.189 | -0.441 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -35.66 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.19 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 544.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.372 | 1.500 | 6.28 | -6.28 | [0 - 1] |
pegRatioTTM | 1.089 | 1.500 | 6.07 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.117 | 1.000 | 9.59 | 0 | [0.1 - 0.5] |
Total Score | 4.60 |
Sawai Group Holdings Co.,
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。